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Aim: The aim of the present study were to elucidate the role of NAMPT in atherosclerosis, by examine
NAMPT expression in peripheral blood mononuclear cells (PBMC) in patients with coronary artery dis-
ease (CAD) and healthy controls and by examining the regulation and effect of NAMPT on macrophage
polarization, hypothesizing that it could inﬂuence the polarization to inﬂammatory and resolving
macrophages.
Method and Results: We analyzed RNA levels of NAMPT in PBMC from CAD and healthy controls and
found NAMPT to be increased in PBMC from patients with acute coronary syndrome (n ¼ 39) compared
to healthy controls (n ¼ 20) and patients with stable CAD (n ¼ 22). Within the PBMC NAMPT was
correlated to several inﬂammatory cytokines and the antioxidant enzyme superoxide dismutase 2.
In vitro cell experiments revealed that NAMPT is increased both intracellular and extracellular in in-
ﬂammatory M1 macrophages compared to in anti-inﬂammatory M2 macrophages. In addition, inhibiting
NAMPT enzymatic activity inhibited M1 polarization in macrophages.
Conclusion: Based on our in vivo and in vitro ﬁndings we suggest that NAMPT could contribute to sys-
temic and plaque inﬂammation in atherosclerotic disorders at least partly through effect on
macrophages.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Inﬂammation is an essential response that enables survival
during infection or injury, and maintains necessary homeostasisslo, Norway.
Ireland Ltd. This is an open accessduring harmful conditions [1]. However, if this response is not
properly regulated, it can result in persistent inﬂammation and
tissue damage such as seen in various autoimmune and auto-
inﬂammatory disorders [2]. Studies suggest that macrophages play
a key role in controlling and terminating such a state of non-
resolving inﬂammation [3].
Atherosclerosis is characterized by accumulation of lipids and
immune cells within the vascular wall, creating an atheroscleroticarticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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in other inﬂammatory conditions, macrophages are of major
importance in regulating atherosclerotic-related inﬂammation, and
various sub-types of macrophages have different phenotypes with
different effects on initiation, progression and maintenance or
resolution of inﬂammatory status [5]. Both inﬂammatory and anti-
inﬂammatory or resolving macrophages are present in the
atherosclerotic lesion, and the balance between these cellular sub-
types is of major importance for the fate of the atherosclerotic
plaque [6e9]. Within the lesion, several factors may modulate the
functional polarization of macrophages, and the picture is further
complicated by the fact that polarized macrophages of the
atherosclerotic plaque retain their plasticity and are capable of
changing phenotypes upon changes in the microenvironment
[10e12]. Thus, while several studies support the importance of
macrophage polarization in atherogenesis, the regulation of these
processes is not fully understood.
Nicotinamide phosphoribosyl transferase (NAMPT) has been
detected in atherosclerotic plaques [13], primarily located to lipid-
loadedmacrophages. NAMPT has also been found to modulate lipid
accumulation and the inﬂammatory status in these cells [14], but its
effect on macrophage function is far from clear. Moreover, while
enhanced NAMPT expression has been reported in carotid athero-
sclerosis [13], whether NAMPT is also regulated within circulating
leukocytes, before entering the lesion, is largely unknown.
To further elucidate the role of NAMPT in atherosclerosis we in
the present study examined NAMPT expression in peripheral blood
mononuclear cells (PBMC) from patients with coronary artery
disease (CAD) and healthy controls and its relation to expression of
inﬂammatory markers within the same cell samples. We also
examined the regulation and effect of NAMPT on macrophage po-
larization, hypothesizing that it could inﬂuence the polarization to
inﬂammatory (i.e., M1) and resolving (i.e., M2) macrophages.
2. Methods
2.1. Study population and PBMC isolation
Patients with CAD veriﬁed by coronary angiography (>50%
stenosis) were included in the study. Patients was classiﬁed into
either stable angina pectoris (SAP) referred to elective coronary
angiography (n ¼ 22), unstable angina pectoris (UAP) or non-ST
elevation myocardial infarction (MI) (NSTEMI) referred to urgent
coronary angiography (n ¼ 19), or patients with ST-elevation MI
(STEMI) (n ¼ 20). SAP was deﬁned as episodes of reversible
ischemic chest pain with signiﬁcant CAD. UAP was deﬁned as
angina at rest or crescendo angina with a clinical indication of ur-
gent (within 48 h) coronary angiography. NSTEMI was deﬁned ac-
cording to the universal deﬁnition of MI as typical rise and fall of
the cardiac speciﬁc biomarker Troponin T (TnT) with at least one
value above the 99th percentile of the upper reference limit in
patients presenting with symptoms of ischemia without any ST
elevation of EKG [15]. STEMI was deﬁned by the same rise in TnT
and ischemic symptoms together with new ST elevation at the J
point in two contiguous leads with the cut-points: 0.1 mV in all
leads other than leads V2eV3where the following cut points apply:
0.2 mV in men 40 years; 0.25 mV in men <40 years, or
0.15 mV in women. or new left bundle-branch block [16]. Clini-
cally unstable patients with cardiac arrest, cardiogenic shock, hy-
potension or pulmonary congestion were not eligible for inclusion.
Patients with active malignant disease, chronic inﬂammatory dis-
ease (eg. inﬂammatory bowel disease, rheumatic arthritis, systemic
lupus erythematosus), intercurrent infection or use of glucocorti-
costeroids, were also excluded. Age matched controls were
recruited from a healthy population based on medical history andclinical evaluation.
The study protocols were approved by the Regional Health Au-
thorities of South-Eastern Norway. The study conﬁrms with the
principles outlined in the Declaration of Helsinki for use of human
tissue or subjects. Signed informed consent was obtained from all
participants.
2.2. Blood sampling and isolation of peripheral blood mononuclear
cells (PBMC)
Blood was sampled for isolation of PBMC and for analysis of
biomarkers including TnT. Venous blood was drawn immediately
before coronary angiography in patients with SAP or UAP/NSTEMI
and arterial blood was drawn in STEMI patients from radial or
femoral artery cannulation before coronary angiography and
percutaneous coronary intervention (PCI) was performed. PBMCs
were isolated from heparinized blood from healthy controls and
CADpatients by Isopaque-Ficoll (Lymphoprep; FreseniusKabiNorge
AS, Oslo, Norway) gradient centrifugation within 1 h after blood
collection and stored in 80 C as cell pellets before RNA isolation.
2.3. Primary human macrophages
Primary monocytes were obtained from buffy coats (The Blood
Bank, Oslo University Hospital, Oslo, Norway). PBMC, isolated as
described above, were seeded in cell plates (10  106/ml; Sigma-
eAldrich) for 2 h before the media was removed and cells were
washed. The adherentmonocytes were then added RPMI 1640 (PAA
Laboratories, Pasching, Austria) supplemented with 10% fetal
bovine serum (Gibco), 1% Penicillin-Streptomycin (SigmaeAldrich)
and Macrophage-colony stimulating factor (M-CSF; 50 ng/ml; R&D
Systems, Minneapolis, MN) for 7 days. Medium was changed every
3 day. The last 18 h lipopolysaccharide (LPS) from E. coli 026:B6
(100 ng/ml, SigmaeAldrich) and interferon (IFN)g (20 ng/ml, R&D
Systems) for M1 differentiation and interleukin (IL)-4 (20 ng/ml,
R&D Systems) for M2 differentiation was added before harvesting.
2.4. Murine bone marrow-derived macrophages
Mice were euthanized by cervical dislocation and bone marrow
cells were harvested frommice femur and tibia from C57BL6Nmice
as described [17,18]. The cells were seeded at 3  106/ml in culture
medium (1640 RPMI [PAA Laboratories], 1% penicillin,10% fetal calf-
serum [FCS], 0.1% gentamycin [SigmaeAldrich]) and incubated for
one week with M-CSF (10 ng/ml; Pepro Tech, Rocky Hill, NY) for
macrophage differentiation. Cells were seeded in 12-well plates
(106/ml), and stimulated with either IFNg (4 ng/ml, Pepro Tech) or
IL-4 (20 ng/ml SigmaeAldrich) for polarization to M1 and M2
macrophages, respectively.
All use of animals were approved and registered by the Nor-
wegian Animal Research authority and conformwith the guidelines
from Directive 2010/63/EU of the European Parliament on the
protection of animals used for scientiﬁc purposes.
2.5. THP-1 cells
The human monocytic cell line THP-1 (American Type Culture
Collection, Rockville, MD) were grown in cell medium (1640 RPMI
[PAA Laboratories], 1% penicillin, 10% FCS, 0.1% gentamycin [Sig-
maeAldrich]) at 37 C with 5% CO2. Before experimental start, the
cells were differentiated into macrophages by incubation with
phorbol myristate acetate (PMA, 100 nM, Sigma Aldrich) for 6 h.
Thereafter, the cells were stimulated with either IFNg (5 ng/ml,
R&D System) and LPS (10 ng/ml, SigmaeAldrich) or IL-4 (25 ng/ml,
R&D System) and IL-13 (25 ng/ml, R&D System) for M1 or M2
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were in addition co-stimulated with the NAMPT enzyme inhibitor
FK866 (100 nM; Axon MedChem) or recombinant NAMPT (200 ng/
ml, Adipogene, San Diego, CA). At different time points, cell-free
supernatants and cell pellets were harvested and stored
at80 C. In all experiments, the vehicle of the stimulus was added
as control.
The selection and concentrations of the different stimuli that
were used for M1 and M2 polarization were based on optimizing
experiments in primary human macrophages, THP-1 macrophages
and murine bone marrow-derived macrophages (BMDM). Veriﬁ-
cation of macrophage polarization was done with gene expression
of appropriate marker [19e23], i.e., human M1 macrophages: tu-
mor necrosis factor (TNF) and IL-6, murine M1 macrophages: TNF
and inducible nitric oxide synthase (iNOS), human M2 macro-
phages: CD163 and peroxome proliferator-activated receptor
(PPAR) g and murine M2 macrophages: arginase 1 (Online
Supplemental Data Table 1).
2.6. RNA analysis
Isolation of RNA was performed using the RNeasy Mini Kit from
Qiagen (Hilden, Germany). RNA was treated with DNase (Ambion,
Austin, TX) to make sure no DNA was left to contaminate, and RNA
was eluted in 30 ml RNase free H2O. Isolated RNA was stored
at 80 C until further analysis. cDNA synthesis was carried out
using High-Capacity cDNA Reverse Transcription Kit (Applied Bio-
systems, Foster City, CA). Quantiﬁcation of mRNA was performed
using qPCR Master Mix for SYBR Green I (Applied Power Master
Mix) and the ABI 9700 (Applied Biosystem) with the accompanying
software SDS 2.3. Primers were designed with the use of primer
express software version 1 (Applied Biosystems), and primer se-
quences can be given upon request. Gene expression of the
housekeeping gene GADPH was used for normalization.
2.7. Measurements of NAMPT and inﬂammatory and anti-
inﬂammatory mediators
Supernatants were analyzed using multiplexing beadTable 1
Clinical and biochemical characteristics of patients with stable coronary artery disease (C
or ST-elevation myocardial infarction (STEMI) referred to coronary angiography.
SAP(N ¼ 22)
Age (years) 62 (51, 68)
Gender (male) 19 (86%)
Hypertension (treated) 14 (78%)
Diabetes (treated) 9 (41%)
Prior PCIa 13 (72%)
Prior CABGb 5 (28%)







Heparin before blood sampling 2 (11%)
Height (cm)/weight (kg) 176/84
sBP (mmHg) 159 (132, 172)
dBP (mmHg) 90 (77, 97)
BMI (kg/m 2^) 27
Peak Troponin T (ng/L) 10 (10, 12)
S-Creatinine (mmol/L) 75 (64, 84)
Categorical data presented as number of total, n (%). Continuous data are presented as m
a PCI, percutaneous coronary intervention.
b CABG, coronary artery bypass grafting.
c ACE: angiotensin converting enzyme, ARB: Angiotensin receptor blocker.technology. Detection of IL-1 receptor antagonist (IL-1ra), IL-4, IL-6,
IL-10, IL-13, TNF (Bio-Plex pro human cytokine assay, Bio-Rad
Laboratories, Hercules, CA) and NAMPT (Visfatin kit from the Hu-
man Diabetes panel, Bio-Rad) were analyzed on a Bio-plex sus-
pension array system using Bio-Plex Manager 6.0 (Bio-Rad
Laboratories) according to the manufacturer's instructions and ac-
cording to their respective instruction manuals. Plasma levels of
myeloperoxidase (MPO) were measured by enzyme immunoassay
obtained from Hycult biotech (Uden, The Netherlands).2.8. Statistics
When comparing more than two groups of individuals, the
KruskaleWallis test was used a priori. If signiﬁcant, Man-
neWhitney U test was used to calculate the difference between
each pair of groups. In the in vitro experiments, t-test and Man-
Whitney U test were used for univariate comparison as appro-
priate. Correlations were calculated by the Spearman rank test. P
values < 0.05 were considered statistical signiﬁcant.3. Results
3.1. NAMPT expression is increased in PBMC from patients with CAD
We have previously found increased NAMPT expression in un-
stable rupture-prone compared to stable atherosclerotic carotid
plaques. Staining of these lesions showed that NAMPT was located
to macrophages [13]. To investigate if NAMPT is increased also in
circulating hematopoietic cells in atherosclerotic disorders, we
measured NAMPTmRNA levels in PBMC isolated from patients with
stable angina pectoris (SAP, n ¼ 20), patients with unstable angina
pectoris (UAP)/NSTEMI (n ¼ 19) and patients with STEMI (n ¼ 20)
as well as healthy controls (n ¼ 20) (Table 1). As shown in Fig. 1,
patients with UAP/NSTEMI and STEMI, but not those with SAP, had
increased NAMPT mRNA levels in PBMC as compared with healthy
controls. For STEMI patients, mRNA levels were also elevated as
compared to SAP, but with no difference between unstable angina/
NSTEMI and STEMI patients (Fig. 1).AD), unstable angina pectoris/Non-ST-elevation myocardial infarction (NSTEMI/UAP)
NSTEMI/UAP(N ¼ 19) STEMI(N ¼ 20)
63 (54, 71) 60 (52, 64)
14 (74%) 16 (80%)
11 (58%) 8 (40%)
8 (42%) 3 (15%)
6 (32%) 3 (15%)
3 (16%) 1 (5%)
4 (22%) 8 (40%)
19 (100%) 2 (35%)
17 (90%) 2 (10%)
15 (79%) 6 (30%)
15 (79%) 6 (30%)
6 (32%) 5 (25%)
0 0
15 (79%) 13 (65%)
172/80 178/80
145 (126, 158) 140 (120, 150)
81 (70, 90) 80 (80, 92)
27 25
80 (46, 631) 3394 (1032, 6804)
70 (61, 99) 70 (63, 92)
edian (interquartile range) unless otherwise noted.
Fig. 1. NAMPT is increased in PBMC from patients with acute coronary syndrome.
The Figure shows NAMPT mRNA levels in PBMC from healthy controls (n ¼ 20), pa-
tients with stable angina pectoris (SAP, n ¼ 20), patients with unstable angina pectoris
(UAP)/NSTEMI (n ¼ 19) and STEMI patients (n ¼ 20). mRNA levels were quantiﬁed by
qPCR and data are given in relation to the control gene GAPDH. Data are presented as
mean and SEM and single values from each individual. **p < 0.005, ****p < 0.0001.
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redox regulation in PBMC from CAD patients
NAMPT is found to be regulated by inﬂammatory cytokines
[13,14]. Within the CAD group as a whole, NAMPT mRNA levels
were correlated with mRNA levels of the inﬂammatory cytokinesFig. 2. NAMPT expression correlates with expression of inﬂammatory markers in PBMC from
(A), CD163 (B), IL-6 (C) and TNF (D) within PBMC from same individuals. mRNA levels were q
in relation to the referece gene GADPH.IL-6 and TNF as well as the monocyte markers CD14 and CD163
within the same PBMC, although the correlation with TNF did not
reach statistical signiﬁcance (Fig. 2). MPO is an important mediator
in atherosclerosis and particularly in plaque destabilization. How-
ever, we found no signiﬁcant correlation between plasma levels of
MPO and NAMPT expression within PBMC in the CAD group
(r ¼ 0.19, p ¼ 0.12). Neutrophils are known as important cellular
sources of MPO, potentially being the main contributor to plasma
levels of MPO. However, both human and murine monocytes ex-
press relatively large amounts of MPO [24,25]. We therefore also
analyzed correlation between NAMPTandMPO expression in PBMC
from the present CAD population However, similar to plasma levels,
we found no correlation between mRNA levels of MPO and NAMPT
within PBMC from the CAD group (r¼ 0.02, p¼ 0.85). NAMPTcould
be involved in the regulation of cellular redox status. We therefore
ﬁnally analyzed the expression of central enzymes involved in
redox regulation in PBMC from patients with CAD and examined
their relation to NAMPT expression in the same cells. While there
was no correlation between NAMPT and CuZn superoxide dismut-
ase 1 (SOD1) (r ¼ 0.18, p ¼ 0.15), mainly found in the cytosol, or
catalase (r ¼ 0.08, p ¼ 0.5), NAMPT expression was strongly
correlated with Mn SOD (SOD2) (r ¼ 0.75, p < 0.001), mainly
located within the mitochondria.3.3. NAMPT expression is increased in inﬂammatory (M1)
macrophages
Macrophages in the atherosclerotic plaque exert great plasticity.
The best characterized macrophages in the human atherosclerotic
plaque are the inﬂammatory M1 macrophages and the anti-
inﬂammatory M2 macrophages [26]. To investigate if NAMPTCAD patients. The panels show correlation between mRNA levels of NAMPT and CD14
uantiﬁed by qPCR in PBMC from the whole CAD population (n ¼ 59) and data are given
Fig. 3. NAMPT gene expression is increased in inﬂammatory M1 macrophages. The
panels show NAMPT mRNA levels in macrophages derived from human monocytes
(buffy coates) (A) and in bone-marrow derived macrophages from C57BL/6N mice (B).
Macrophages were polarized to M1 macrophages by LPS (100 ng/ml) and IFNg (20 ng/
ml), in murine macrophages only IFNg (4 ng/ml) was used, and to M2 macrophages by
IL-4 (20 ng/ml) after culturing for 18 h mRNA levels of NAMPT were analyzed by qPCR
in relation to expression of the reference gene GAPDH. The concentrations of the
different stimuli were based on preliminary doseeresponse experiments. Data are
given as mean and SEM (n ¼ 3) in relation to NAMPT expression in control cells.
*p < 0.05 and **p < 0.01 versus M2 macrophages and controls.
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M1 (LPS/IFNg polarized), and M2 (IL-4 polarized) macrophages
from primary human monocytes and from BMDM from C57BL/6N
mice. NAMPT was highly up-regulated in the inﬂammatory M1
macrophages compared to non-polarized control cells and M2
macrophages, while NAMPT expression in M2 macrophages was
not different from control cells (Fig. 3). The same pattern was seen
in both human monocyte-derived macrophages and in BMDM in
mice (Fig. 3AeB).
3.4. NAMPT expression increases during macrophage polarization
To study the regulation of NAMPT during macrophage polari-
zation in more detail, we examined the time course of NAMPT
expression during THP-1 macrophage polarization. As previously
shown, NAMPT expression increases during PMA differentiation
from monocytes to macrophages [14], and interestingly, NAMPT
expression increased even further during the ﬁrst 3 h of M1 po-
larization, and stayed at that level during 24 h polarization (Fig. 4).
Concordant with the ﬁndings in Fig. 3 NAMPT levels did not
markedly change during M2 polarization, with only modest or no
increase after PMAmacrophage differentiation (Fig. 4). For bothM1
and M2 differentiation, the same pattern was seen at the mRNA
(Fig. 4A) and the protein level (measurements in cell supernatants,
Fig. 4B), demonstrating regulation of both intracellular and extra-
cellular NAMPT during M1 polarization.
3.5. NAMPT inhibition during polarization pushes the macrophage
towards a less inﬂammatory phenotype
Our data show that NAMPT is up-regulated during M1 polari-
zation. To investigate if this is only a secondary phenomenon (i.e.,
reﬂect M1 polarization) or if NAMPT itself could modulate macro-
phage polarization, we polarized THP-1 macrophages towards the
inﬂammatory M1 (LPS/IFNg) phenotype with and without FK866, a
non-competitive inhibitor of intracellular NAMPT enzyme activity.
As seen in Fig. 5A, NAMPT inhibition down-regulated both TNF and
IL-6 mRNA levels and secretion, with no effects on IL-4, IL-10, IL-1
receptor antagonist (IL-1Ra) and IL-13, representing typical M1 and
M2 related cytokines, respectively. In contrast, PPARg and CD163,
representing additional markers of M2 macrophage polarization,
was up-regulated during FK866 exposure, although the increase in
CD163 did not reach statistical signiﬁcance (Fig. 5B). In contrast to
the effect of enzyme inhibition (i.e., FK866), recombinant extra-
cellular NAMPT and the NAMPT substrate vitamin B3, had no effect
on polarization markers (data not shown).
4. Discussion
NAMPT is elevated in symptomatic atherosclerotic carotid pla-
que [13], and increased serum levels of NAMPT have been associ-
ated with recent ischemic cerebral events in patients with carotid
atherosclerosis [27]. Our ﬁndings in the present study suggest that
increased NAMPT expression in atherosclerotic disorders is not
restricted to immune cells within the atherosclerotic lesion, but is
also found in circulating mononuclear cells. Thus, we found that
patients with acute coronary syndrome (ACS) have increased
NAMPT expression in PBMC as compared with those with stable
CAD and healthy controls, with particularly high levels in STEMI
patients, correlated with inﬂammatory markers and SOD2
expression in these cells. Together with our in vitro ﬁndings sug-
gesting a link between NAMPT and inﬂammatory M1macrophages,
these ﬁndings suggest that NAMPT could promote an inﬂammatory
phenotype in monocytes/macrophages both systemically and
within the lesion, potentially contributing to plaque progressionand destabilization. A recent study by Nencioni et al. showing that
the NAMPT inhibitor FK866 attenuate plaque inﬂammation in
atherosclerotic mice (ApoE/) on western diet further support
such a notion [28].
Macrophages show great plasticity and the macrophage
phenotype ranges from inﬂammatory to anti-inﬂammatory, usually
referred to as M1 and M2 macrophages, respectively. We have
previously found that NAMPT is localized tomacrophages in carotid
plaques [13], and we and others have shown that NAMPT could
promote inﬂammatory responses in this cell population [13,29]. In
the atherosclerotic lesion NAMPT seems to be located in the
rupture-prone, macrophage rich areas [13]. These areas have been
suggested to be dominated by pro-inﬂammatory M1 macrophages
[22]. In this study we show that NAMPT is markedly up-regulated
during M1 polarization as opposed to no or only modest changes
during M2 polarization. This was shown in three different model
systems, i.e., THP-1 macrophages, primary human monocyte-
derived macrophages and murine BMDM. These ﬁndings further
link NAMPT to an inﬂammatory macrophage phenotype, poten-
tially being one of several characteristics of these macrophages.
Macrophage polarization is a fairly new ﬁeld of research. The
alternative activation of murinemacrophages was ﬁrst proposed by
Fig. 4. NAMPT expression and secretion increases during M1 polarization. NAMPT
expression was analyzed in PMA differentiated THP-1 macrophages before and during
polarization to M1 macrophages by LPS (10 ng/ml) and IFNg (5 ng/ml) and to M2
macrophages by IL-4 (20 ng/ml) and IL-13 (25 ng/ml). Control cells were not exposed
to polarization stimuli. Panel A shows NAMPT mRNA levels as assessed by qPCR in
relation to the reference gene GAPDH. Panel B shows protein levels of NAMPT in su-
pernatants. Note that the cell culture media was exchanged before polarization. Data
are given as mean and SEM (n ¼ 3). h, hours. *p < 0.05 and **p < 0.01 versus M2
macrophages and control cells.
Fig. 5. Inhibition of NAMPT activity during M1 polarization pushes the macrophage
towards a less inﬂammatory phenotype. We polarized THP-1 cells towards the in-
ﬂammatory M1 phenotype by LPS (10 ng/ml) and IFNg (5 ng/ml) with and without the
NAMPT inhibitor FK866 (1000 nM) and cell pellet and cell supernatants were har-
vested after 24 h. Panel A shows mRNA levels in relation to the control gene GAPDH as
assessed by qPCR and panel B shows protein levels in cell supernatants. Data are given
in relation to levels without FK866 (mean and SEM, n ¼ 3). P < 0.05 versus M1
polarized macrophages without FK866.
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described in 2002 [30]. In the present studywe show that NAMPT is
not only up-regulated during M1 polarization, it seems to push the
macropheages in a M1 direction. Thus, we found that inhibition of
NAMPT enzymatic activity in macrophages by FK866 down-
regulated the inﬂammatory cytokines IL-6 and TNF, with no effect
on the anti-inﬂammatory mediators IL-1ra, IL-4, IL-10 and IL-13.
Moreover, NAMPT inhibition also enhanced the expression of
CD163 and PPARg in these cells, thought to be markers of M2
macrophages. The regulation of macrophages polarization is not
completely understood. Our ﬁndings suggest that NAMPT enzy-
matic activity could contribute to this process. Venter et al. have
recently showed that FK866 promotes downregulation of meta-
bolic activity in macrophages accompanied by impaired phagocytic
and adhesion capacity in these cells [31]. Moreover, intracellular
NAD levels have been shown to regulate TNF in a sirtuin-dependent
manner in THP-1 macrophages [32]. These ﬁndings further link
NAMPT enzymatic activity and macrophage-mediated
inﬂammation.
NAMPT exists in both extracellular and intracellular forms,
mediating cytokine-like and enzymatic activity, respectively.
Intracellular NAMPT is the rate limiting enzyme in the salvage
pathway of NAD generation and its mechanisms of action involve
regulation of intracellular metabolic activity and interaction with
various intracellular pathways such as sirtuins [33]. In contrast, the
mechanism of action of extracellular NAMPT is poorly understood.
In the present study we show that M1 polarization of macrophages
increases both mRNA levels and the release of NAMPT protein intocell supernatants suggesting some common regulation. However,
whereas inhibition of NAMPT enzymatic activity attenuated M1
polarization, no effect was seen of extracellular NAMPT. On the
other hand, we and others have previously shown inﬂammatory
effect of extracellular NAMPT in macrophages [13,29]. Moreover,
Audrito et al. recently reported that extracellular NAMPT promotes
M2 polarization in PBMC from patients with chronic lymphocytic
leukemia (CLL) [34]. The reasons for these discrepancies are not
clear but could involve differences in the NAMPT proteins that are
used in these experiments (e.g., degree of glycosylation). Moreover,
it is conceivable that cellular activation and metabolic status will
affect the inﬂuence of NAMPT, and macrophages in patients with
CLL will clearly differ from macrophages from healthy controls.
Nonetheless, the mechanisms of action of extracellular NAMPT as
well as its regulation need to be further clariﬁed.5. Conclusion
We have previously shown increased NAMPT expression in
symptomatic carotid plaques, primarily located to macrophages
[13]. Herein we show enhanced NAMPT expression in PBMC from
patients with ACS (i.e., UAP/NSTEMI and STEMI) with particulary
high levels in STEMI patients. Together with our in vitro (NAMPT
promotes M1 polarization), these data may suggest that NAMPT
could contribute to systemic and plaque inﬂammation in athero-
sclerotic disorders at least partly through its effect onmacrophages.
However, these results do not prove any causal relationship
B. Halvorsen et al. / Atherosclerosis 243 (2015) 204e210210between NAMPT and atherogenesis. Although anti-inﬂammatory
effect was recently shown through NAMPT inhibition in ApoE/
mice on western diet [28], further studies on the effect of NAMPT
inhibition or overexpression in experimental models of athero-
sclerosis will be of major importance to prove any causal role of
NAMPT in the development and progression of atherosclerotic
disorders. Although we previously have found NAMPT to colo-
calized to lipid loaded macrophages in carotid plaque [13] and to
modulate lipid loading [14]. The role of NAMPTand lipid loading are
rater complex and this essential process in atherosclerosis has to be
studied further.
Sources of funding






Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.atherosclerosis.2015.09.010.
References
[1] R. Medzhitov, Inﬂammation 2010: new adventures of an old ﬂame, Cell 140
(2010) 771e776.
[2] C. Nathan, Points of control in inﬂammation, Nature 420 (2002) 846e852.
[3] I. Tabas, Macrophage death and defective inﬂammation resolution in
atherosclerosis, Nat. Rev. Immunol. 10 (2010) 36e46.
[4] C.K. Glass, J.L. Witztum, Atherosclerosis. The road ahead, Cell 104 (2001)
503e516.
[5] D.M. Mosser, J.P. Edwards, Exploring the full spectrum of macrophage acti-
vation, Nat. Rev. Immunol. 8 (2008) 958e969.
[6] E. Galkina, K. Ley, Immune and inﬂammatory mechanisms of atherosclerosis
(*), Annu. Rev. Immunol. 27 (2009) 165e197.
[7] M.A. Bouhlel, B. Derudas, E. Rigamonti, et al., PPARgamma activation primes
human monocytes into alternative M2 macrophages with anti-inﬂammatory
properties, Cell Metab. 6 (2007) 137e143.
[8] J. Frostegard, A.K. Ulfgren, P. Nyberg, et al., Cytokine expression in advanced
human atherosclerotic plaques: dominance of pro-inﬂammatory (Th1) and
macrophage-stimulating cytokines, Atherosclerosis 145 (1999) 33e43.
[9] S.W. Waldo, Y. Li, C. Buono, et al., Heterogeneity of human macrophages in
culture and in atherosclerotic plaques, Am. J. Pathol. 172 (2008) 1112e1126.
[10] J. Khallou-Laschet, A. Varthaman, G. Fornasa, et al., Macrophage plasticity in
experimental atherosclerosis, PloS One 5 (2010) e8852.
[11] R.D. Stout, C. Jiang, B. Matta, et al., Macrophages sequentially change their
functional phenotype in response to changes in microenvironmental in-
ﬂuences, J. Immunol. 175 (2005) 342e349.
[12] J.E. Feig, S. Parathath, J.X. Rong, et al., Reversal of hyperlipidemia with a ge-
netic switch favorably affects the content and inﬂammatory state ofmacrophages in atherosclerotic plaques, Circulation 123 (2011) 989e998.
[13] T.B. Dahl, A. Yndestad, M. Skjelland, et al., Increased expression of visfatin in
macrophages of human unstable carotid and coronary atherosclerosis:
possible role in inﬂammation and plaque destabilization, Circulation 115
(2007) 972e980.
[14] T. Dahl, T. Ranheim, S. Holm, et al., Nicotinamide phosphoribosyltransferase
and lipid accumulation in macrophages, Eur. J. Clin. Invest 41 (2011)
1098e1104.
[15] K. Thygesen, J.S. Alpert, A.S. Jaffe, et al., Third universal deﬁnition of
myocardial infarction, Eur. Heart J. 33 (2012) 2551e2567.
[16] P.G. Steg, S.K. James, D. Atar, et al., ESC Guidelines for the management of
acute myocardial infarction in patients presenting with ST-segment elevation,
Eur. Heart J. 33 (2012) 2569e2619.
[17] D.A. Hume, S. Gordon, Optimal conditions for proliferation of bone marrow-
derived mouse macrophages in culture: the roles of CSF-1, serum, Ca2þ,
and adherence, J. Cell. Physiol. 117 (1983) 189e194.
[18] E. Kanters, M. Pasparakis, M.J. Gijbels, et al., Inhibition of NF-kappaB activation
in macrophages increases atherosclerosis in LDL receptor-deﬁcient mice,
J. Clin. Invest. 112 (2003) 1176e1185.
[19] M. Munder, K. Eichmann, M. Modolell, Alternative metabolic states in murine
macrophages reﬂected by the nitric oxide synthase/arginase balance:
competitive regulation by CD4þ T cells correlates with Th1/Th2 phenotype,
J. Immunol. 160 (1998) 5347e5354.
[20] J.W. Tjiu, J.S. Chen, C.T. Shun, et al., Tumor-associated macrophage-induced
invasion and angiogenesis of human basal cell carcinoma cells by
cyclooxygenase-2 induction, J. Invest. Dermatol. 129 (2009) 1016e1025.
[21] I. Caras, C. Tucureanu, L. Lerescu, et al., Inﬂuence of tumor cell culture su-
pernatants on macrophage functional polarization: in vitro models of
macrophage-tumor environment interaction, Tumori 97 (2011) 647e654.
[22] J.L. Stoger, M.J. Gijbels, S. van der Velden, et al., Distribution of macrophage
polarization markers in human atherosclerosis, Atherosclerosis 225 (2012)
461e468.
[23] F.O. Martinez, S. Gordon, M. Locati, et al., Transcriptional proﬁling of the hu-
man monocyte-to-macrophage differentiation and polarization: new mole-
cules and patterns of gene expression, J. Immunol. 177 (2006) 7303e7311.
[24] E. Grage-Griebenow, H.D. Flad, M. Ernst, Heterogeneity of human peripheral
blood monocyte subsets, J. Leukoc. Biol. 69 (2001) 11e20.
[25] F.K. Swirski, M. Wildgruber, T. Ueno, et al., Myeloperoxidase-rich Ly-6Cþ
myeloid cells inﬁltrate allografts and contribute to an imaging signature of
organ rejection in mice, J. Clin. Invest. 120 (2010) 2627e2634.
[26] G. Chinetti-Gbaguidi, S. Colin, B. Staels, Macrophage subsets in atherosclerosis,
Nat. Rev. Cardiol. 12 (2015) 10e17.
[27] Q. Kong, M. Xia, R. Liang, et al., Increased serum visfatin as a risk factor for
atherosclerosis in patients with ischaemic cerebrovascular disease, Singap.
Med. J. 55 (2014) 383e387.
[28] A. Nencioni, R.F. da Silva, R.A. Fraga-Silva, et al., Nicotinamide phosphor-
ibosyltransferase inhibition reduces intraplaque CXCL1 production and asso-
ciated neutrophil inﬁltration in atherosclerotic mice, Thromb. Haemost. 111
(2014) 308e322.
[29] A.R. Moschen, A. Kaser, B. Enrich, et al., Visfatin, an adipocytokine with
proinﬂammatory and immunomodulating properties, J. Immunol. 178 (2007)
1748e1758.
[30] C.F. Anderson, D.M. Mosser, A novel phenotype for an activated macrophage:
the type 2 activated macrophage, J. Leukoc. Biol. 72 (2002) 101e106.
[31] G. Venter, F.T. Oerlemans, M. Willemse, et al., NAMPT-mediated salvage
synthesis of NADþ controls morphofunctional changes of macrophages, PloS
One 9 (2014) e97378.
[32] F. Van Gool, M. Galli, C. Gueydan, et al., Intracellular NAD levels regulate tu-
mor necrosis factor protein synthesis in a sirtuin-dependent manner, Nat.
Med. 15 (2009) 206e210.
[33] T.B. Dahl, S. Holm, P. Aukrust, et al., Visfatin/NAMPT: a multifaceted molecule
with diverse roles in physiology and pathophysiology, Annu. Rev. Nutr. 32
(2012) 229e243.
[34] V. Audrito, S. Serra, D. Brusa, et al., Extracellular nicotinamide phosphor-
ibosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic
lymphocytic leukemia, Blood 125 (2015) 111e123.
